0001645113-22-000020.txt : 20220307
0001645113-22-000020.hdr.sgml : 20220307
20220307182357
ACCESSION NUMBER: 0001645113-22-000020
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220303
FILED AS OF DATE: 20220307
DATE AS OF CHANGE: 20220307
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shah Pritesh
CENTRAL INDEX KEY: 0001744884
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37565
FILM NUMBER: 22719705
MAIL ADDRESS:
STREET 1: C/O NOVOCURE INC.
STREET 2: 20 VALLEY STREAM PARKWAY, SUITE 300
CITY: MALVERN
STATE: PA
ZIP: 19355
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NovoCure Ltd
CENTRAL INDEX KEY: 0001645113
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: NO. 4 THE FORUM
STREET 2: GRENVILLE STREET
CITY: ST. HELIER
STATE: Y9
ZIP: JE2 4UF
BUSINESS PHONE: 44 (0)15 3475 6700
MAIL ADDRESS:
STREET 1: NO. 4 THE FORUM
STREET 2: GRENVILLE STREET
CITY: ST. HELIER
STATE: Y9
ZIP: JE2 4UF
FORMER COMPANY:
FORMER CONFORMED NAME: Novocure Ltd
DATE OF NAME CHANGE: 20150615
4
1
wf-form4_164669542266568.xml
FORM 4
X0306
4
2022-03-03
0
0001645113
NovoCure Ltd
NVCR
0001744884
Shah Pritesh
C/O NOVOCURE INC.,
20 VALLEY STREAM PARKWAY, SUITE 300
MALVERN
PA
19355
0
1
0
0
Chief Commercial Officer
Ordinary Shares
2022-03-03
4
A
0
21714
0
A
95226
D
Ordinary Shares
2022-03-03
4
S
0
997
74.498
D
94229
D
Ordinary Shares
2022-03-04
4
S
0
2632
73.34
D
91597
D
Ordinary Shares
2022-03-04
4
S
0
1914
70.407
D
89683
D
Options to Buy Ordinary Shares
80.59
2022-03-03
4
A
0
38027
80.59
A
2023-03-01
2032-02-29
Ordinary Shares
38027.0
38027
D
Options to Buy Ordinary Shares
80.59
2022-03-03
4
A
0
6231
80.59
A
2023-03-01
2032-02-29
Ordinary Shares
6231.0
6231
D
Represents restricted share units that are scheduled to vest in equal installments on each of March 21, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Options to buy 38,027 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
Options to buy 6,231 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.
By: /s/ Steven Robbins, Attorney in fact for Pritesh Shah
2022-03-07